Interleukin 21-induced granzyme b-expressing b cells infiltrate tumors and regulate t cells

Cancer Research

Volumn 73, Issue 8, 2013, Pages 2468-2479

  Lindner, Stefanie ^a   Dahlke, Karen ^b   Sontheimer, Kai ^b   Hagn, Magdalena ⁱ   Kaltenmeier, Christof ^a   Barth, Thomas F E ^c   Beyer, Thamara ^a   Reister, Frank ^d   Fabricius, Dorit ^e   Lotfi, Ramin ^a,f   Lunov, Oleg ^b   Nienhaus, G Ulrich ^b,g,h   Simmet, Thomas ^b   Kreienberg, Rolf ^d   Moller, Peter ^c   Schrezenmeier, Hubert ^a,f   Jahrsdorfer, Bernd ^a,f,j  

^a Institutes of Transfusion Medicine   (Germany)

^b Pharmacology of Natural Products and Clinical Pharmacology ^*  (Germany)

^c Departments of Pathology   (Germany)

^d Gynecology and Obstetrics   (Germany)

^e UNIVERSITY OF ULM   (Germany)

^f University of Ulm   (Germany)

^g Applied Physics   (Germany)

^h KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

ⁱ PETER MACCALLUM CANCER CENTRE   (Australia)

^j German Red Cross Blood Transfusion Service Baden Württemberg Hessen and University Hospital Ulm   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; CD147 ANTIGEN; CD19 ANTIGEN; CD1D ANTIGEN; CD38 ANTIGEN; CD5 ANTIGEN; GRANZYME B; IMMUNOGLOBULIN M; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 21; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ZETA CHAIN; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MALE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SOLID TUMOR; TUMOR MICROENVIRONMENT;

ANTIGENS, CD5; APOPTOSIS; B-LYMPHOCYTES, REGULATORY; CELL COMMUNICATION; CELLS, CULTURED; GRANZYMES; HUMANS; IMMUNOPHENOTYPING; INTERLEUKINS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS; PHENOTYPE; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; TOLL-LIKE RECEPTORS; TUMOR MICROENVIRONMENT;

EID: 84876991334     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-3450     Document Type: Article

References (47)

1. Lampropoulou V, Calderon-Gomez E, Roch T, Neves P, Shen P, Stervbo U, et al. Suppressive functions of activated B cells in autoimmune diseases reveal the dual roles of Toll-like receptors in immunity. Immunol Rev 2010;233:146-61.
2. Bouaziz JD, Yanaba K, Tedder TF. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev 2008;224:201-14.
3. Mauri C, Gray D, Mushtaq N, Londei M. Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 2003;197:489-501.
4. Wagner U, Kaltenhauser S, Pierer M, Wilke B, Arnold S, Hantzschel H. B lymphocytopenia in rheumatoid arthritis is associated with the DRB1 shared epitope and increased acute phase response. Arthritis Res 2002;4:R1.
5. Yanaba K, Bouaziz JD, Haas KM, Poe JC, Fujimoto M, Tedder TF. A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 2008;28:639-50.
6. DiLillo DJ, Matsushita T, Tedder TF. B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann N Y Acad Sci 2010;1183:38-57.
7. Matsushita T, Yanaba K, Bouaziz JD, Fujimoto M, Tedder TF. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest 2008;118:3420-30.
8. Blair PA, Norena LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR, et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 2010;32:129-40.
9. Iwata Y, Matsushita T, Horikawa M, DiLillo DJ, Yanaba K, Venturi GM, et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 2011;117: 530-41.
10. Martin F, Chan AC. B cell immunobiology in disease: Evolving concepts from the clinic. Annu Rev Immunol 2006;24:467-96.
11. Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000;408: 57-63.
12. Jin H, Carrio R, Yu A, Malek TR. Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bimdependent apoptosis. J Immunol 2004;173:657-65.
13. Ettinger R, Sims GP, Fairhurst AM, Robbins R, da Silva YS, Spolski R, et al. IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J Immunol 2005;175:7867-79.
14. Ozaki K, Spolski R, Feng CG, Qi CF, Cheng J, Sher A, et al.Acritical role for IL-21 in regulating immunoglobulin production. Science 2002;298: 1630-4.
15. Hagn M, Ebel V, Sontheimer K, Schwesinger E, Lunov O, Beyer T, et al. CD5+ B cells from individuals with systemic lupus erythematosus express granzyme B. Eur J Immunol 2010;40:2060-9.
16. Hagn M, Schwesinger E, Ebel V, Sontheimer K, Maier J, Beyer T, et al. Human B cells secrete granzyme B when recognizing viral antigens in the context of the acute phase cytokine IL-21. J Immunol 2009;183: 1838-45.
17. Gondek DC, Lu LF, Quezada SA, Sakaguchi S, Noelle RJ. Cutting edge: Contact-mediated suppression by CD4+CD25+regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol 2005;174:1783-6.
18. Salti SM, Hammelev EM, Grewal JL, Reddy ST, Zemple SJ, Grossman WJ, et al. Granzyme B regulates antiviral CD8+ T cell responses. J Immunol 2011;187:6301-9.
19. Vignali DA, Collison LW, Workman CJ.Howregulatory T cells work. Nat Rev Immunol 2008;8:523-32.
20. Jahrsdörfer B, Vollmer A, Blackwell SE, Maier J, Sontheimer K, Beyer T, et al. Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion. Blood 2010;115:1156-65.
21. Spolski R, Leonard WJ. IL-21 is an immune activator that also mediates suppression via IL-10. Crit Rev Immunol 2010;30:559-70.
22. Yoshizaki A, Miyagaki T, Dilillo DJ, Matsushita T, Horikawa M, Kountikov EI, et al. Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature 2012;491:264-8.
23. Buzza MS, Bird PI. Extracellular granzymes: Current perspectives. Biol Chem 2006;387:827-37.
24. Spaeny-Dekking EH, Hanna WL, Wolbink AM, Wever PC, Kummer AJ, Swaak AJ, et al. Extracellular granzymes A and B in humans: Detection of native species during CTL responses in vitro and in vivo. J Immunol 1998;160:3610-6.
25. Holm C, Nyvold CG, Paludan SR, Thomsen AR, Hokland M. Interleukin-21 mRNA expression during virus infections. Cytokine 2006;33: 41-5.
26. Ettinger R, Kuchen S, Lipsky PE. The role of IL-21 in regulating B-cell function in health and disease. Immunol Rev 2008;223:60-86.
27. Nelson BH. CD20+ B cells: The other tumor-infiltrating lymphocytes. J Immunol 2010;185:4977-82.
28. Milne K, Kobel M, Kalloger SE, Barnes RO, Gao D, Gilks CB, et al. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS ONE 2009;4:e6412.
29. Martinet L, Garrido I, Filleron T, Le Guellec S, Bellard E, Fournie JJ, et al. Human solid tumors contain high endothelial venules: Association with T-and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res 2011;71:5678-87.
30. Kuroda H, Tamaru J, Sakamoto G, Ohnisi K, Itoyama S. Immunophenotype of lymphocytic infiltration in medullary carcinoma of the breast. Virchows Arch 2005;446:10-4.
31. Watt V, Ronchese F, Ritchie D. Resting B cells suppress tumor immunity via an MHC class-II dependent mechanism. J Immunother 2007;30:323-32.
32. Perricone MA, Smith KA, Claussen KA, Plog MS, Hempel DM, Roberts BL, et al. Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes. J Immunother 2004;27:273-81.
33. Dong HP, Elstrand MB, Holth A, Silins I, Berner A, Trope CG, et al. NKand B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. Am J Clin Pathol 2006;125:451-8.
34. Wieckowski E, Wang GQ, Gastman BR, Goldstein LA, Rabinowich H. Granzyme B-mediated degradation of T-cell receptor zeta chain. Cancer Res 2002;62:4884-9.
35. Diaz-Alderete A, Crispin JC, Vargas-Rojas MI, Alcocer-Varela J. IL-10 production in B cells is confined to CD154+ cells in patients with systemic lupus erythematosus. J Autoimmun 2004;23:379-83.
36. Hwu P, Du MX, Lapointe R, Do M, Taylor MW, Young HA. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol 2000;164:3596-9.
37. Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol 2007; 8:1353-62.
38. Scheffold A, Murphy KM, Hofer T. Competition for cytokines: T(reg) cells take all. Nat Immunol 2007;8:1285-7.
39. Solstad T, Bains SJ, Landskron J, Aandahl EM, Thiede B, Tasken K, et al. CD147 (Basigin/Emmprin) identifies FoxP3+CD45RO+CTLA4+activated human regulatory T cells. Blood 2011;118:5141-51.
40. Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S, et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005;202:1131-9.
41. Konforte D, Simard N, Paige CJ. IL-21: An executor of B cell fate. J Immunol 2009;182:1781-7.
42. Gray D, Gray M. What are regulatory B cells? Eur J Immunol 2010; 40:2677-9.
43. Tretter T, Venigalla RK, Eckstein V, Saffrich R, Sertel S, Ho AD, et al. Induction of CD4+ T-cell anergy and apoptosis by activated human B cells. Blood 2008;112:4555-64.
44. Boivin WA, Shackleford M, Vanden Hoek A, Zhao H, Hackett TL, Knight DA, et al. Granzyme B cleaves decorin, biglycan and soluble betaglycan, releasing active transforming growth factor-beta1. PLoS ONE 2012;7:e33163.
45. Coronella-Wood JA, Hersh EM. Naturally occurring B-cell responses to breast cancer. Cancer Immunol Immunother 2003;52:715-38.
46. De Boniface J, Poschke I, Mao Y, Kiessling R. Tumor-dependent down-regulation of the zeta-chain in T-cells is detectable in early breast cancer and correlates with immune cell function. Int J Cancer 2012;131:129-39.
47. Petrella TM, Tozer R, Belanger K, Savage KJ, Wong R, Smylie M, et al. Interleukin-21 has activity in patients with metastatic melanoma: A phase II study. J Clin Oncol 2012;30:3396-401.